What is ImmunoReagents?
ImmunoReagents, Inc. operates as a critical manufacturer of high-quality reagents, serving the pharmaceutical, biotechnology, and in vitro diagnostics sectors. The company specializes in the production of primary and secondary antibodies, immunoassay reagents, and advanced antibody purification tools. By providing essential components for complex applications such as ELISA, IHC, and Western blotting, ImmunoReagents has established itself as a vital OEM partner. Their commitment to cost-effective, high-performance solutions enables research institutions and diagnostic developers to maintain rigorous standards in their analytical workflows.
How much funding has ImmunoReagents raised?
ImmunoReagents has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in ImmunoReagents
PPP
Public-Private Partnership
What's next for ImmunoReagents?
Following this late-stage financing, ImmunoReagents is expected to prioritize the scaling of its manufacturing infrastructure to meet the rising demand for diagnostic assay components. The strategic allocation of this capital will likely focus on enhancing R&D capabilities and optimizing supply chain resilience. As the biotechnology industry continues to emphasize precision medicine and rapid diagnostic development, ImmunoReagents is poised to leverage its technical expertise to capture additional market share, solidifying its role as a foundational supplier in the life science research ecosystem.
See full ImmunoReagents company page
